The Readout Loud
Episode 167: George Yancopoulos on biotech in 2021, plus a CRISPR milestone, Biogen's FDA saga,
This episode isn’t summarized yet
Create a free account and summarize it. In a few minutes you’ll have the key takeaways and a section-by-section summary.
Show notes
First we talk to George Yancopoulos, head scientist at Regeneron Pharmaceuticals, about the future of CRISPR genome editing and the latest idea for treating obesity. Then, we discuss STAT's reporting on the cozy relationship between Biogen and the FDA ahead of Aduhelm's approval and what the ensuing fallout might mean. Before all that, we chat about the latest news in biotech, including vaccine boosters and a decadelong debacle.